BioClin Therapeutics, Inc., a San Leandro, CA-based clinical stage drug development company, raised an additional $20m in funding reaching $50m in Series B financing.
New investors Sectoral Asset Management and INKEF Capital joined existing investors Sofinnova Ventures, Ysios Capital, HealthCap, Tekla Capital Management funds, and Life Sciences Partners (LSP) in the round.
The company, which has raised a total of $79m since its founding, will use the funds to advance its lead development candidate, B-701, for the treatment of patients with metastatic bladder cancer, or metastatic urothelial carcinoma (mUC).
Led by Stephen Lau, CEO, BioClin Therapeutics develops an anti-FGFR3 (fibroblast growth factor receptor 3) monoclonal antibody for metastatic bladder cancer and to broaden its clinical development activities.
The company has ongoing clinical studies in metastatic bladder cancer including B-701 monotherapy, and B-701 in combination with standard-of-care chemotherapy, as well as with pembrolizumab, an immune checkpoint inhibitor.